Botulinum toxin treatment of myofascial pain: a critical review of the literature
- PMID: 22777564
- DOI: 10.1007/s11916-012-0287-6
Botulinum toxin treatment of myofascial pain: a critical review of the literature
Abstract
This is a review of literature relevant to the treatment of myofascial pain syndrome by botulinum injections. The objective is to critically review the studies to see if they are appropriately designed, conducted, and interpreted to provide guidance in the management of myofascial pain. The intent is to better understand the mixed results that these studies have provided. A search was made utilizing PubMed for literature relevant to the use of botulinum toxin in the treatment of myofascial pain. All identifiable series were reviewed, including open label, single-blinded and double-blinded studies, randomized and controlled, or not. In general, small case series of only a few patients were not included unless they made a relevant point and there were no available randomized studies or larger studies. Single case reports were not included. This is not a meta-analysis. The studies were evaluated according to their design and the selection of outcome measurements, and the interpretation of results. The studies were individually critiqued, and an overall assessment and commentary was made of the studies in the field as a whole. Problems that were common to the studies were robust placebo responders, incomplete treatment of a regional myofascial pain syndrome, inappropriate or confounding control populations or treatments, and inappropriate time periods for assessment of outcomes, or misinterpretation of the time-frame of action of botulinum toxin. The studies of the effect of botulinum toxin treatment of myofascial trigger points have had mixed results. However, few studies have been designed to avoid many of the pitfalls associated with a trial of botulinum toxin treatment of trigger points. Better-designed studies may give results that can be used to guide practice based on reliable evidence. At the present time, one must conclude that the available evidence is insufficient to guide clinical practice.
Similar articles
-
An update on botulinum toxin A injections of trigger points for myofascial pain.Curr Pain Headache Rep. 2014 Jan;18(1):386. doi: 10.1007/s11916-013-0386-z. Curr Pain Headache Rep. 2014. PMID: 24338700 Review.
-
The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial.Clin J Pain. 2006 Jan;22(1):90-6. doi: 10.1097/01.ajp.0000151871.51406.c3. Clin J Pain. 2006. PMID: 16340597 Clinical Trial.
-
Botulinum toxin in the treatment of myofascial pain syndrome.Pain. 1994 Oct;59(1):65-69. doi: 10.1016/0304-3959(94)90048-5. Pain. 1994. PMID: 7854804 Clinical Trial.
-
Efficacy and Safety of Single Botulinum Toxin Type A (Botox®) Injection for Relief of Upper Trapezius Myofascial Trigger Point: A Randomized, Double-Blind, Placebo-Controlled Study.J Med Assoc Thai. 2015 Dec;98(12):1231-6. J Med Assoc Thai. 2015. PMID: 27004309 Clinical Trial.
-
A critical appraisal of the evidence for botulinum toxin type A in the treatment for cervico-thoracic myofascial pain syndrome.Pain Pract. 2014 Feb;14(2):185-95. doi: 10.1111/papr.12074. Epub 2013 May 21. Pain Pract. 2014. PMID: 23692187 Review.
Cited by
-
Botulinum toxin for the treatment of myofascial pain syndromes involving the neck and back: a review from a clinical perspective.Evid Based Complement Alternat Med. 2013;2013:381459. doi: 10.1155/2013/381459. Epub 2013 Feb 19. Evid Based Complement Alternat Med. 2013. PMID: 23533477 Free PMC article.
-
Dexmedetomidine inhibits abnormal muscle hypertrophy of myofascial trigger points via TNF-α/ NF-κB signaling pathway in rats.Front Pharmacol. 2022 Nov 3;13:1031804. doi: 10.3389/fphar.2022.1031804. eCollection 2022. Front Pharmacol. 2022. PMID: 36408215 Free PMC article.
-
Myofascial low back pain treatment.Curr Pain Headache Rep. 2014 Sep;18(9):449. doi: 10.1007/s11916-014-0449-9. Curr Pain Headache Rep. 2014. PMID: 25091133 Review.
-
Effects of intraplantar botulinum toxin-B on carrageenan-induced changes in nociception and spinal phosphorylation of GluA1 and Akt.Eur J Neurosci. 2016 Jul;44(1):1714-22. doi: 10.1111/ejn.13261. Epub 2016 May 19. Eur J Neurosci. 2016. PMID: 27108664 Free PMC article.
-
Clinical implication of latent myofascial trigger point.Curr Pain Headache Rep. 2013 Aug;17(8):353. doi: 10.1007/s11916-013-0353-8. Curr Pain Headache Rep. 2013. PMID: 23801006 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical